COLON ADENOCARCINOMA
Clinical trials for COLON ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new COLON ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for COLON ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to stop BRAF colon cancer in its tracks
Disease control OngoingThis study tests whether adding two targeted drugs (encorafenib and cetuximab) after standard surgery and chemotherapy can lower the chance of cancer coming back in people with a specific genetic type of stage II/III colon cancer (BRAF V600E). Participants either receive the drug…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
New combo shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis study tests a combination of two drugs, cabozantinib and nivolumab, in people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if the combination can stop or shrink the cancer for at least 16 weeks. About 48 adults with a spec…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New combo therapy tested for High-Risk colon cancer patients
Disease control OngoingThis study looked at over 2,400 people with stage II colon cancer who had surgery and were at high risk for the cancer coming back. It compared standard chemotherapy (5-FU, leucovorin, and oxaliplatin) with the same drugs plus bevacizumab, a targeted therapy that blocks blood ves…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Immunotherapy combo may keep stage III colon cancer at bay
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can better prevent colon cancer from coming back in people with stage III colon cancer that has a specific DNA repair problem (dMMR). About 712 participants will receive either chemothera…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Scientists hunt for genetic clues behind rising colorectal cancer in young adults
Knowledge-focused OngoingThis study explores genetic and lifestyle factors that may raise the risk of colorectal cancer in people under 50. Researchers will compare data from 818 patients and their family members to find genetic markers linked to early-onset disease. The goal is to better understand who …
Matched conditions: COLON ADENOCARCINOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 14, 2026 12:06 UTC